Remdesivir Market, By Product (10 Mm*1 Ml in Dmso, 5mg, 10mg, 50mg, and 100mg), By Application (Hospital, Clinics, Drug Store, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Remdesivir (GS-5734) is a nucleoside analogue prodrug. It has inhibitory effects on pathogenic animal and human coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in-vitro and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models. In India, ICMR has approved remdesivir under Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 infection. Cipla has launched remdesivir under the brand name Cipremi (remdesivir lyophilised powder for injection 100 mg).

Impact of Covid-19 pandemic on market

Along with Covid-19 infections growing worldwide, governments of all Covid-19 hit nations are suffering from a shortage of essential medical supplies in order to provide optimum care to infected patients. Multiple therapeutic institutes globally are working to come up with a reliable treatment for Covid-19. One such treatment includes the use of hydroxychloroquine, while another is the use of antiviral drugs used in the disease management of HIV. Both these treatments have huge demand from advanced antivirals and antimalarial drugs. This leads the drug manufacturers as an off label indication for these drug classes has to be worked upon. The report will account for Covid19 as a key market contributor.

Demand for drugs and other related products is growing exponentially globally in order to prepare for a potential outbreak. This is a key factor projected to boost market growth to a significant extent. Major companies in the biotech industry, including research organizations such as the National Institutes of Health (NIH), US and pharmaceutical companies are being assisted by governments to develop novel vaccines and drugs to tackle this deadly virus. The key players present involved in the development of novel drugs for treating coronavirus include Cipla Limited, AbbVie Inc., Regeneron Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., and companies exploring the development of vaccines as a preventive measure include Novavax, Inc. and Inovio Pharmaceuticals, Inc. Other main factors include increasing concerns regarding outbreaks at regular intervals, rising spending on the healthcare sector, and growing need to protect the population from known and unknown viruses. Conversely, the time required for each phase of clinical trials and high cost associated with research and development of therapeutic drugs and vaccines are among some of the major factors that might limit market growth to a certain limit.

The remdesivir market is segmented based on product, application, and region.

On the basis of product, the remdesivir market is segmented into 10 Mm*1 Ml in Dmso, 5mg, 10mg, 50mg, and 100mg. On the basis of application, the global market is classified into hospital, clinics, drug store, and others.

On region, the remdesivir market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Currently, in Japan, remdesivir is approved as a treatment for patients infected with SARS-CoV-2, the virus that causes COVID-19. The U.S. Food and Drug Administration (FDA) granted remdesivir an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. This authorization is on a temporary basis and does not take the place of the formal new drug application submission, review and approval process.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the remdesivir market report based on product, application, and region.

Remdesivir Market, By Product:

• 10 Mm*1 Ml In Dmso
• 5mg
• 10mg
• 50mg
• 100mg

Remdesivir Market, By Application:

• Hospital
• Clinics
• Drug Store
• Others

Remdesivir Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the remdesivir market includes Cipla Limited, Gilead Sciences, Kelun Pharma, Bright Gene, Hunan Warrant Pharmaceutical, and Hainan Haiyao. The key players present are involved in the development of novel drugs for treating coronavirus and are also involved in exploring the development of vaccines as a preventive measure. For instance, on June 20202, Gilead Sciences, Inc. declared topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming period.

• Gilead Sciences
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cipla Limited
• Kelun Pharma
• Bright Gene
• Hunan Warrant Pharmaceutical
• Hainan Haiyao

 “*” marked represents similar segmentation in other categories in the respective section